Retinal Biologics Market (Drug Class - TNF-alpha Inhibitor, and VEGF-A Antagonist; Indication - Macular Degeneration, Diabetic Retinopathy, and Uveitis; Distribution Channel - Hospitals, Clinics, and Pharmacies): Global Industry Analysis, Trends, Size, Share and Forecasts to 2030

Retinal Biologics Market (Drug Class - TNF-alpha Inhibitor, and VEGF-A Antagonist; Indication - Macular Degeneration, Diabetic Retinopathy, and Uveitis; Distribution Channel - Hospitals, Clinics, and Pharmacies): Global Industry Analysis, Trends, Size, Share and Forecasts to 2030

Report Code: IGR0432 Category: Healthcare & Medical Devices Published: January, 2024

A recent report published by Infinium Global Research on retinal biologics market provides in-depth analysis of segments and sub-segments in the global as well as regional retinal biologics market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional retinal biologics market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global retinal biologics market.

Market Insight:

The retinal biologics market was valued at USD 20.13 billion in 2022 and is expected to reach USD 47.11 billion in 2030, with a CAGR of 11.20% during the forecast period.

Retinal biologics refers to the pharmaceutical sector focused on the development, production, and distribution of biological therapies designed to address various retinal disorders and conditions. These biologics are often intricate, utilizing living organisms or components derived from living systems to target specific molecular or cellular pathways associated with retinal diseases. The market encompasses a range of innovative treatments, including monoclonal antibodies, gene therapies, and other biotechnological interventions, aimed at providing effective solutions for conditions such as diabetic retinopathy, macular degeneration, and other retinal abnormalities. Factors influencing the retinal biologics market include the prevalence of retinal diseases, advancements in biotechnology, regulatory frameworks, and ongoing research and development initiatives. Challenges may include regulatory hurdles, production complexities, and the need for skilled professionals. Overall, the retinal biologics market represents a crucial frontier in medical innovation, offering the potential for improved therapeutic outcomes and vision care for individuals affected by various retinal disorders.

The rising prevalence of retinal diseases is propelling the growth of the market. The increasing menace of diabetic retinopathy, leading to vision impairment in both type I and type II diabetes sufferers, is a pressing concern. Often culminating in diabetic macular edema characterized by macular swelling, this condition, along with the rising prevalence of retinal disorders like uveitis and orbital inflammation, amplifies the demand for retinal drugs and biologics. Additionally, the aging global population serves as a significant driver for the retinal biologics market. As the elderly demographic expands, the prevalence of Age-related Macular Degeneration (AMD) and other retinal disorders increases, fueling the demand for advanced therapeutic solutions. Retinal biologics, with their innovative approaches like gene therapies and biologics-based treatments, offer promising avenues for managing and treating these conditions. The growing patient pool and the need for effective, targeted treatments contribute to the sustained growth of the retinal biologics market as it addresses the specific challenges associated with retinal diseases prevalent in the aging population. However, stringent regulatory processes, high development costs, and limited reimbursement policies may hinder the market's growth. Furthermore, advancements in biotechnology and the increasing prevalence of retinal disorders create a lucrative opportunity for market growth.

Global retinal biologics market Size, Share, Trends, Industr | IGR

The global retinal biologics market is segmented into North America, Europe, Asia Pacific, and the rest of the world. During the projected period, North America is expected to hold the largest share of the retinal biologics market. The region's continuous enhancements in healthcare infrastructure, coupled with a rising incidence of retinal illnesses and favorable reimbursement policies, are anticipated to propel market expansion. The presence of key manufacturing players and increased healthcare spending further contribute to driving growth in the North American market. Along with this, the robust healthcare infrastructure in North America facilitates the adoption of advanced retinal biologics, providing a conducive environment for their development, approval, and distribution. The region's proactive approach to implementing cutting-edge medical technologies, coupled with supportive reimbursement frameworks, positions it as a key player in the global retinal biologics landscape. Moreover, Asia Pacific is anticipated to capture a significant share of the market, owing to the heightened focus on researching retinal biologics and the surge in the prevalence of eye-related disorders contributing to the escalating market growth in this region. Furthermore, the expanding elderly demographic provides additional support to the retinal biologics market. Notably, China dominates the market share in the Asia-Pacific region for retinal biologics, while the Indian market exhibits the fastest growth in this sector.

Report Scope of the Retinal Biologics Market:

Report Coverage Details
Market Size in 2022 USD 20.13 Billion
Market Size by 2030 USD 47.11 Billion
Growth Rate from 2023 to 2030 CAGR of 11.20%
Largest Market North America
No. of Pages 255
Market Drivers
  • The rising prevalence of retinal diseases is propelling the growth of the market.

  • The aging global population serves as a significant driver for the Retinal Biologics Market.

Market Segmentation By Drug Class, By Indication, and By Distribution Channel
Regional Scope North America, Europe, Asia Pacific, and RoW

Segment Covered

The report on global retinal biologics market covers segments such as drug class, indication, and distribution channel. On the basis of drug class, the sub-markets include tnf-alpha inhibitor, and vegf-a antagonist. On the basis of indication, the sub-markets include macular degeneration, diabetic retinopathy, and uveitis. On the basis of distribution channel, the sub-markets include hospitals, clinics, and pharmacies.

Companies Profiled:

The report provides profiles of the companies in the market such as Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc., MeiraGTx Limited, Novartis AG, Coherus BioSciences, Inc., Oxurion NV, Bayer AG, and Spark Therapeutics, Inc..

Report Highlights:

The report provides deep insights into demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the retinal biologics market. Moreover, the study highlights current market trends and provides forecasts from 2023-2030. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.


Frequently Asked Questions (FAQ's)

The global retinal biologics market was valued at USD 20.13 Billion in 2022.
It is likely to grow at a CAGR of 11.20% during the forecast period 2023-2030.
The global retinal biologics market is estimated to reach USD 47.11 Billion by the end of 2030.
North America is anticipated to exhibit high demand for retinal biologics market during the forecast period.
Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc., MeiraGTx Limited, Novartis AG, Coherus BioSciences, Inc., Oxurion NV, Bayer AG, and Spark Therapeutics, Inc..
CHOOSE LICENCE TYPE

Please Choose One of them.

Google translate
© 2024. Infinium Global Research LLP. All Rights Reserved.